Agios Pharmaceuticals, Inc. (AGIO) CEO Sells $383,100.00 in Stock
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 6,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $63.85, for a total value of $383,100.00. The sale was disclosed in a filing with the SEC, which is available at this link.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up $4.48 during midday trading on Friday, hitting $66.49. The company had a trading volume of 354,476 shares, compared to its average volume of 410,645.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.63) EPS. equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.89 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in AGIO. BlackRock Inc. lifted its holdings in Agios Pharmaceuticals by 8,463.5% during the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after buying an additional 2,141,768 shares during the period. FMR LLC lifted its holdings in Agios Pharmaceuticals by 14.1% during the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after buying an additional 895,584 shares during the period. Vanguard Group Inc. raised its position in shares of Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Agios Pharmaceuticals by 748.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after acquiring an additional 572,579 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth about $20,423,000. 93.46% of the stock is currently owned by hedge funds and other institutional investors.
AGIO has been the topic of a number of recent research reports. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective on the stock. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $75.70.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.